Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.

Name: Kaimen Rigor review — Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.
Item: Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.
Rating: 94
Author: Alpha1

Gay F, Roeloffzen W, Dimopoulos MA, Rosiñol L, van der Klift M, Mina R, Oriol A, Katodritou E, Wu KL, Rodríguez Otero P, Hájek R, Antonioli E, van Duin M, D'Agostino M, Martínez-López J, van Leeuwen-Segarceanu EM, Zamagni E, van de Donk NWCJ, Weisel KC, Pour L, Radocha J, Belotti A, Schjesvold F, Bladé J, Einsele H, Sonneveld P, Boccadoro M, Broijl A

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 2.25★ (Weak), 0 critical, 2 high issues for “Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.

Read full text (PMC)

DOI

10.1038/s41591-026-04282-0

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/86760545-3484-48aa-9991-5f2f30d4c106" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/86760545-3484-48aa-9991-5f2f30d4c106/badge" alt="Kaimen Rigor review — 2.25★ (Weak), 0 critical, 2 high issues for “Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

97d87d99e3f9c8e848d5ec266c7e3460cef15a62bd882af008719d0c9e0676ae

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.

Paper source

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

2.25 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is MRD negativity by NGS, a surrogate biomarker. Although the paper cites FDA ODAC support and references linking MRD to PFS/OS, it does not demonstrate target engagement at the tested dose (e.g., PK/PD) nor provide a validated surrogate-to-clinical-outcome link specific to this trial. The PFS data are immature, so the clinical benefit is not directly established.
“The primary endpoint was the rate of measurable residual disease (MRD) negativity (sensitivity of 10 −5 or better) by next-generation sequencing (NGS) after consolidation.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary effect is a difference in MRD negativity rates (77% vs 67%, OR 1.67). While statistically significant, the clinical meaningfulness is not anchored to a minimal clinically important difference or a direct clinical outcome. The effect size is presented as a surrogate improvement without evidence that it translates into improved survival or quality of life.
“Post-consolidation MRD negativity was significantly higher with Isa-KRd versus KRd at the 10 −5 (77% versus 67%; odds ratio (OR) 1.67, P = 0.049)”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 103AuthenticityData authenticity concerns 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit6 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted randomized phase 3 trial with a clear scientific premise, rigorous design, and transparent reporting. The main weakness is the data/code availability statement, which is vague and lacks a formal access mechanism, and the absence of a code-sharing statement. Minor copyedit issues include inconsistent superscript formatting and an unclear discontinuation count.

Both reviewers classified the study as interventional; no disagreement. The evaluation covered all eight dimensions; bench-resource criteria (antibodies, cell lines, mycoplasma) were not applicable for this drug trial. The statistics verification recomputed 10 reported tests consistently, but this covers only a subset of tests; the paper's statistics should not be considered fully verified beyond those checks.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 10 tests: 10 consistent, 0 inconsistent; 6 recomputed directly from the reported test statistics, 4 via agent-written checks.

Overstated conclusions

3 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

8 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

1 finding · worst low

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

3 integrity concerns flagged (0 high).

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites multiple prior studies (FORTE, MIDAS, GMMG-CONCEPT) and explains the rationale for comparing Isa-KRd vs KRd, noting the lack of randomized trials for this quadruplet. Limitations of prior research (e.g., single-arm studies) are acknowledged, and the trial aims to address this gap. The premise is well-supported.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on carfilzomib, isatuximab, and MRD as an endpoint, and provides a logical rationale for the trial.

Evidence

“In the phase 2 UNITO-MM-01/FORTE trial, carfilzomib–lenalidomide–dexamethasone (KRd) plus ASCT resulted in high rates of pre-maintenance measurable residual disease (MRD) negativity (sensitivity of 10 −5 , 62%) and median progression-free survival (PFS; 99 months)”

Introduction ¶1Find in source

“This trial aims to show the superiority of Isa-KRd versus KRd to support the use of a new quadruplet option for the treatment of patients with NDMM, in the absence of randomized trials evaluating quadruplets that combine KRd with anti-CD38 mAbs, as only single-arm studies have been initiated.”

Introduction ¶4Find in source

“as only single-arm studies have been initiated”

Introduction ¶4Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with extensive prior work cited and a logical rationale for the study.

Evidence

“On the basis of its efficacy in the relapse setting, carfilzomib has been investigated in several studies involving transplant-eligible (TE) patients with NDMM.”

Main, paragraph 1-3Find in source

Main, paragraph 3Find in source

“in the absence of randomized trials evaluating quadruplets that combine KRd with anti-CD38 mAbs, as only single-arm studies have been initiated.”

Main, paragraph 3Find in source

Randomization method is described (computer-generated, block randomization, stratified by ISS and cytogenetic risk). Power analysis is provided for the primary and key secondary endpoints. Inclusion/exclusion criteria are detailed. Outlier handling is addressed via ITT analysis and single imputation for missing MRD data. Controls are inherent in the randomized comparison. Independent replication is not applicable for a single pivotal trial. Blinding is not performed (open-label), but this is explicitly stated.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: randomized, open-label, with a pre-specified sample size calculation, stratification, and a hierarchical testing procedure. Blinding is not applicable due to open-label design, but this is stated.

Evidence

“At enrollment, a computer system randomly assigned patients (1:1) to treatment into one of the two induction and consolidation arms. Patients were stratified according to International Staging System (ISS) stage (I versus II versus III) and cytogenetic risk assessed by fluorescence in situ hybridization (high risk (presence of t(4;14) and/or t(14;16) and/or del(17p)) versus standard risk or missing (none of these abnormalities)) and then randomized using a web-based, computer-generated procedure completely concealed from study participants.”

MethodsFind in source

“The calculation of the sample size for the primary endpoint was done with the following assumptions, considering the ITT population: α = 0.05 (two-sided), β = 0.10 and post-ASCT full-dose consolidation MRD negativity (sensitivity of 10 −5 , by NGS) rate: Isa-KRd 64% versus KRd 45%. The total number of patients required was 300 (by the χ 2 test with Yates’ continuity correction).”

Statistical analysisFind in source

“The EMN24 IsKia trial is a randomized, open-label, phase 3 trial”

MethodsFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with adequate randomization, blinding (open-label with rationale), power analysis, and inclusion/exclusion criteria.

Evidence

“At enrollment, a computer system randomly assigned patients (1:1) to treatment into one of the two induction and consolidation arms.”

MethodsFind in source

Statistical analysisFind in source

“The EMN24 IsKia trial is a randomized, open-label, phase 3 trial”

MethodsFind in source

Table 1 reports age (median and IQR), sex (female/male counts and percentages), and ECOG performance status. Health status is implied by inclusion criteria (e.g., ECOG ≤2, organ function). Species/strain and housing are not applicable for a human trial. Demographics are adequately reported.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Patient demographics (age, sex, ECOG status) are reported in Table 1. Sex is reported for both arms, and since both sexes are enrolled, sex justification is not applicable. Age and health status are reported.

Evidence

“Age (years) Median (IQR) | 61 (55–66) | 60 (54–63) | | Sex Female Male | 72 (48) 79 (52) | 67 (44) 84 (56)”

Table 1Find in source

“ECOG performance status b 0 1 2 | 88 (58) 51 (34) 12 (8) | 93 (62) 51 (34) 7 (5)”

Table 1Find in source

PASSReviewer 2· 90% conf

Biological variables are adequately reported for a human trial, including sex, age, and demographics.

Evidence

“Sex Female Male | 72 (48) 79 (52) | 67 (44) 84 (56)”

Table 1Find in source

“Age (years) Median (IQR) | 61 (55–66) | 60 (54–63)”

Table 1Find in source

“ECOG performance status b 0 1 2 | 88 (58) 51 (34) 12 (8) | 93 (62) 51 (34) 7 (5)”

Table 1Find in source

The paper states approval by the ethics committee of the coordinating center (Comitato etico territoriale Lombardia 6, Italy) and that all patients gave written informed consent. Regulatory compliance is stated (Declaration of Helsinki and Good Clinical Practice). This is a human interventional trial, so IACUC is not applicable.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval is documented with a named ethics committee, and informed consent is described. The trial is registered and conducted per Declaration of Helsinki and GCP.

Evidence

“This trial and its Protocol and amendments were approved by the ethics or institutional review boards at each of the participating centers (ethics committee of the coordinating center: Comitato etico territoriale Lombardia 6, Italy).”

MethodsFind in source

“All patients gave written informed consent before participating in the trial, which was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals are adequately reported with named ethics committee and informed consent.

Evidence

MethodsFind in source

“All patients gave written informed consent before participating in the trial”

MethodsFind in source

“which was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.”

MethodsFind in source

The drugs are named with manufacturers implied (Sanofi for isatuximab, Amgen for carfilzomib) and detailed dosing regimens are provided. The MRD assay is performed by Adaptive Biotechnologies, which is identified. Software tools (R, REDCap) are identified. Since this is a drug trial, bench criteria are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational products (isatuximab, carfilzomib, lenalidomide, dexamethasone) are identified with doses and schedules. Statistical software (R v4.2.1) is identified. No antibodies, cell lines, or mycoplasma testing are applicable.

Evidence

“Patients in the KRd arm received 4 28-day induction cycles with KRd (carfilzomib 20 mg m −2 intravenously administered (IV) on day 1 of cycle 1, followed by 56 mg m −2 IV on days 8 and 15 of cycle 1, then 56 mg m −2 IV on days 1, 8 and 15 for all subsequent doses; lenalidomide 25 mg orally administered (PO) on days 1–21; dexamethasone 40 mg on days 1, 8, 15 and 22)”

MethodsFind in source

“Statistical analyses were done with R (v4.2.1).”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

Key resources are adequately identified, including investigational drugs and software.

Evidence

MethodsFind in source

“Statistical analyses were done with R (v4.2.1).”

Statistical analysisFind in source

“Study data were collected and managed using Research Electronic Data Capture (REDCap, developed by the REDCap Consortium)”

Data availabilityFind in source

The paper reports ORs with 95% CIs and exact p-values (e.g., P = 0.049). Assumptions are handled by design (ITT, logistic regression adjusted for stratification). Data presentation includes tables and figures with CIs. Mathematical plausibility is not applicable for large-N continuous outcomes. No demonstrable errors found.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical tests are named (logistic regression, Fisher's exact, Clopper-Pearson), effect sizes with CIs are reported, software is identified, and data presentation is appropriate for a clinical trial. Exact p-values are reported for primary and secondary endpoints.

Evidence

“the 10 −5 MRD negativity rate after post-ASCT full-dose consolidation was significantly higher in the Isa-KRd arm versus the KRd arm (116 (77%) versus 101 (67%) patients, odds ratio (OR) 1.67, 95% CI 1.00–2.80, P = 0.049).”

ResultsFind in source

“Logistic regression models were used to estimate ORs and their 95% CIs and P values for the analyses of binary endpoints, response criteria (as defined by the IMWG) and MRD rates.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Statistical analysis is rigorous with named tests, exact p-values, effect sizes with CIs, and software identified.

Evidence

“Logistic regression models were used to estimate ORs and their 95% CIs and P values for the analyses of binary endpoints”

Statistical analysisFind in source

“odds ratio (OR) 1.67, 95% CI 1.00–2.80, P = 0.049”

ResultsFind in source

“OR 2.36, 95% CI 1.47–3.79, P = 0.0004”

ResultsFind in source

The data availability statement says deidentified data will be made available upon reasonably justified request to the sponsor, but does not specify a data access committee or platform, and the response time is vague ('typically'). Code availability is not reported; only the software used is mentioned. For a clinical trial, managed access is acceptable, but the statement lacks concrete details.

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

A data availability statement is present but vague: data are not publicly available and only available upon request to the sponsor with no clear mechanism or timeframe beyond 'typically 3 months'. Code is not shared.

Evidence

“After the publication of this article, deidentified data collected for this analysis and related documents will be made available upon reasonably justified request, which needs to be written and addressed to the attention of the sponsor of the EMN24 IsKia trial, the European Myeloma Network (EMN), at the following e-mail address: info@emn.life.”

Data availabilityFind in source

absence[Code availability]

Code sharing is not reported.

PASSReviewer 2· 90% conf

Data availability is adequately described with a concrete access route, and code is described.

Evidence

Data availabilityFind in source

“Response will typically be given in 3 months.”

Data availabilityFind in source

“All statistical analyses were performed using R software (v4.2.1).”

Data availabilityFind in source

Trial is registered (NCT04483739). A reporting summary is linked. Limitations are discussed (immature PFS, post hoc analyses). Conclusions are proportional. Funding and competing interests are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered (NCT04483739), methods are detailed, limitations are discussed, conclusions are proportional, and funding/COI are disclosed. A reporting guideline is not explicitly mentioned but the paper includes a reporting summary.

Evidence

“ClinicalTrials.gov registration: NCT04483739”

AbstractFind in source

“Due to the current Statistical Analysis Plan (), the current follow-up of our trial does not yet allow for the evaluation of data on sustained MRD negativity beyond 1 year and for a comparison of PFS between the two arms.”

DiscussionFind in source

“Sanofi and Amgen provided the funding to conduct the trial, with no role in the design and conduct of the study”

FundingFind in source

PASSReviewer 2· 95% conf

Reporting is transparent with trial registration, reporting summary, limitations discussed, and funding/COI statements.

Evidence

“ClinicalTrials.gov registration: NCT04483739”

AbstractFind in source

“Further information on research design is available in the linked to this article.”

AbstractFind in source

DiscussionFind in source

Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CARE.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 56 references by DOI: 2 verified — 54 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly consistency, clarity, other.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and methodologically sound; an informed reader should weigh the minor data-access vagueness and the lack of code sharing as transparency limitations, but these do not undermine the validity of the reported results. No erratum is warranted based on the identified issues, though the discontinuation count discrepancy in the Results section should be clarified.

1.
HIGHdata code
In the Data Availability section, specify a concrete data access mechanism (e.g., a data access committee or a platform like Vivli) and a maximum response time instead of 'typically 3 months'.
The current statement is vague and does not meet common transparency standards for clinical trial data sharing.
2.
HIGHdata code
Add a Code Availability statement, even if it states that no custom code was used or that analysis code is available upon request.
The absence of any code-sharing statement is a reporting gap that reviewers may flag.
3.
MEDIUMreporting
In the Methods or Reporting Summary, explicitly name the reporting guideline followed (e.g., CONSORT).
Naming the guideline strengthens transparency and aligns with journal expectations.
4.
MEDIUMcopyedit
In the Results section, clarify the reasons for the remaining 2 discontinuations in the Isa-KRd arm during post-ASCT full-dose consolidation (9 total, 5 AEs, 2 deaths).
The numbers do not sum to the total, which could confuse readers and raise questions about data completeness.
5.
MEDIUMcopyedit
Standardize superscript formatting for '10^-5' and '10^-6' throughout the abstract and main text.
Inconsistent formatting is a minor but noticeable copyedit issue.
6.
MEDIUMreporting
In the Abstract, specify the primary endpoint time point (post-consolidation) for the MRD negativity result.
Clarifying the time point improves precision and avoids ambiguity.
7.
MEDIUMreporting
In the Methods, clarify that the power calculation for the first key secondary endpoint is distinct from the primary endpoint calculation.
The current sentence is long and could be misread as the primary power calculation.
8.
MEDIUMreporting
Report the exact number of patients with missing MRD data at each time point and the reasons for missingness.
Enhances transparency of the imputation approach and supports reproducibility.
9.
MEDIUMreporting
Provide a CONSORT flow diagram in the main text or supplement.
A flow diagram improves reporting completeness for a randomized trial.
10.
LOWreporting
In the Discussion, emphasize that the 10^-6 MRD analysis was exploratory and not prespecified.
Avoids overinterpretation of exploratory findings.
11.
LOWreporting
Report the results of pre-specified subgroup analyses with confidence intervals for all subgroups, not just selected ones.
Complete subgroup reporting supports transparency and reduces selective reporting concerns.
12.
LOWreporting
Include a statement on the validation of the NGS assay used for MRD detection.
Provides context for the reliability of the primary endpoint measurement.

Full text (73,605 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.

Read full text (PMC)

DOI

10.1038/s41591-026-04282-0

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/86760545-3484-48aa-9991-5f2f30d4c106" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/86760545-3484-48aa-9991-5f2f30d4c106/badge" alt="Kaimen Rigor review — 2.25★ (Weak), 0 critical, 2 high issues for “Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

97d87d99e3f9c8e848d5ec266c7e3460cef15a62bd882af008719d0c9e0676ae

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

2.25 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is MRD negativity by NGS, a surrogate biomarker. Although the paper cites FDA ODAC support and references linking MRD to PFS/OS, it does not demonstrate target engagement at the tested dose (e.g., PK/PD) nor provide a validated surrogate-to-clinical-outcome link specific to this trial. The PFS data are immature, so the clinical benefit is not directly established.
“The primary endpoint was the rate of measurable residual disease (MRD) negativity (sensitivity of 10 −5 or better) by next-generation sequencing (NGS) after consolidation.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary effect is a difference in MRD negativity rates (77% vs 67%, OR 1.67). While statistically significant, the clinical meaningfulness is not anchored to a minimal clinically important difference or a direct clinical outcome. The effect size is presented as a surrogate improvement without evidence that it translates into improved survival or quality of life.
“Post-consolidation MRD negativity was significantly higher with Isa-KRd versus KRd at the 10 −5 (77% versus 67%; odds ratio (OR) 1.67, P = 0.049)”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 103AuthenticityData authenticity concerns 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit6 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 10 tests: 10 consistent, 0 inconsistent; 6 recomputed directly from the reported test statistics, 4 via agent-written checks.

Overstated conclusions

3 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

8 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

1 finding · worst low

Other integrity concernAssessed

3 integrity concerns flagged (0 high).

Reporting gaps

1 finding · worst medium

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on carfilzomib, isatuximab, and MRD as an endpoint, and provides a logical rationale for the trial.

Evidence

Introduction ¶1Find in source

Introduction ¶4Find in source

“as only single-arm studies have been initiated”

Introduction ¶4Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with extensive prior work cited and a logical rationale for the study.

Evidence

“On the basis of its efficacy in the relapse setting, carfilzomib has been investigated in several studies involving transplant-eligible (TE) patients with NDMM.”

Main, paragraph 1-3Find in source

Main, paragraph 3Find in source

“in the absence of randomized trials evaluating quadruplets that combine KRd with anti-CD38 mAbs, as only single-arm studies have been initiated.”

Main, paragraph 3Find in source

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Evidence

MethodsFind in source

Statistical analysisFind in source

“The EMN24 IsKia trial is a randomized, open-label, phase 3 trial”

MethodsFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with adequate randomization, blinding (open-label with rationale), power analysis, and inclusion/exclusion criteria.

Evidence

“At enrollment, a computer system randomly assigned patients (1:1) to treatment into one of the two induction and consolidation arms.”

MethodsFind in source

Statistical analysisFind in source

“The EMN24 IsKia trial is a randomized, open-label, phase 3 trial”

MethodsFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Evidence

“Age (years) Median (IQR) | 61 (55–66) | 60 (54–63) | | Sex Female Male | 72 (48) 79 (52) | 67 (44) 84 (56)”

Table 1Find in source

“ECOG performance status b 0 1 2 | 88 (58) 51 (34) 12 (8) | 93 (62) 51 (34) 7 (5)”

Table 1Find in source

PASSReviewer 2· 90% conf

Biological variables are adequately reported for a human trial, including sex, age, and demographics.

Evidence

“Sex Female Male | 72 (48) 79 (52) | 67 (44) 84 (56)”

Table 1Find in source

“Age (years) Median (IQR) | 61 (55–66) | 60 (54–63)”

Table 1Find in source

“ECOG performance status b 0 1 2 | 88 (58) 51 (34) 12 (8) | 93 (62) 51 (34) 7 (5)”

Table 1Find in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval is documented with a named ethics committee, and informed consent is described. The trial is registered and conducted per Declaration of Helsinki and GCP.

Evidence

MethodsFind in source

“All patients gave written informed consent before participating in the trial, which was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals are adequately reported with named ethics committee and informed consent.

Evidence

MethodsFind in source

“All patients gave written informed consent before participating in the trial”

MethodsFind in source

“which was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Evidence

MethodsFind in source

“Statistical analyses were done with R (v4.2.1).”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

Key resources are adequately identified, including investigational drugs and software.

Evidence

MethodsFind in source

“Statistical analyses were done with R (v4.2.1).”

Statistical analysisFind in source

“Study data were collected and managed using Research Electronic Data Capture (REDCap, developed by the REDCap Consortium)”

Data availabilityFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Evidence

ResultsFind in source

“Logistic regression models were used to estimate ORs and their 95% CIs and P values for the analyses of binary endpoints, response criteria (as defined by the IMWG) and MRD rates.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Statistical analysis is rigorous with named tests, exact p-values, effect sizes with CIs, and software identified.

Evidence

“Logistic regression models were used to estimate ORs and their 95% CIs and P values for the analyses of binary endpoints”

Statistical analysisFind in source

“odds ratio (OR) 1.67, 95% CI 1.00–2.80, P = 0.049”

ResultsFind in source

“OR 2.36, 95% CI 1.47–3.79, P = 0.0004”

ResultsFind in source

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

Evidence

Data availabilityFind in source

absence[Code availability]

Code sharing is not reported.

PASSReviewer 2· 90% conf

Data availability is adequately described with a concrete access route, and code is described.

Evidence

Data availabilityFind in source

“Response will typically be given in 3 months.”

Data availabilityFind in source

“All statistical analyses were performed using R software (v4.2.1).”

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Evidence

“ClinicalTrials.gov registration: NCT04483739”

AbstractFind in source

DiscussionFind in source

“Sanofi and Amgen provided the funding to conduct the trial, with no role in the design and conduct of the study”

FundingFind in source

PASSReviewer 2· 95% conf

Reporting is transparent with trial registration, reporting summary, limitations discussed, and funding/COI statements.

Evidence

“ClinicalTrials.gov registration: NCT04483739”

AbstractFind in source

“Further information on research design is available in the linked to this article.”

AbstractFind in source

DiscussionFind in source

Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CARE.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 56 references by DOI: 2 verified — 54 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly consistency, clarity, other.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHdata code
In the Data Availability section, specify a concrete data access mechanism (e.g., a data access committee or a platform like Vivli) and a maximum response time instead of 'typically 3 months'.
The current statement is vague and does not meet common transparency standards for clinical trial data sharing.
2.
HIGHdata code
Add a Code Availability statement, even if it states that no custom code was used or that analysis code is available upon request.
The absence of any code-sharing statement is a reporting gap that reviewers may flag.
3.
MEDIUMreporting
In the Methods or Reporting Summary, explicitly name the reporting guideline followed (e.g., CONSORT).
Naming the guideline strengthens transparency and aligns with journal expectations.
4.
MEDIUMcopyedit
In the Results section, clarify the reasons for the remaining 2 discontinuations in the Isa-KRd arm during post-ASCT full-dose consolidation (9 total, 5 AEs, 2 deaths).
The numbers do not sum to the total, which could confuse readers and raise questions about data completeness.
5.
MEDIUMcopyedit
Standardize superscript formatting for '10^-5' and '10^-6' throughout the abstract and main text.
Inconsistent formatting is a minor but noticeable copyedit issue.
6.
MEDIUMreporting
In the Abstract, specify the primary endpoint time point (post-consolidation) for the MRD negativity result.
Clarifying the time point improves precision and avoids ambiguity.
7.
MEDIUMreporting
In the Methods, clarify that the power calculation for the first key secondary endpoint is distinct from the primary endpoint calculation.
The current sentence is long and could be misread as the primary power calculation.
8.
MEDIUMreporting
Report the exact number of patients with missing MRD data at each time point and the reasons for missingness.
Enhances transparency of the imputation approach and supports reproducibility.
9.
MEDIUMreporting
Provide a CONSORT flow diagram in the main text or supplement.
A flow diagram improves reporting completeness for a randomized trial.
10.
LOWreporting
In the Discussion, emphasize that the 10^-6 MRD analysis was exploratory and not prespecified.
Avoids overinterpretation of exploratory findings.
11.
LOWreporting
Report the results of pre-specified subgroup analyses with confidence intervals for all subgroups, not just selected ones.
Complete subgroup reporting supports transparency and reduces selective reporting concerns.
12.
LOWreporting
Include a statement on the validation of the NGS assay used for MRD detection.
Provides context for the reliability of the primary endpoint measurement.

Full text (73,605 chars)Analyzed: Aug 15, 2026